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Abstract
Genetic disruption of myostatin or its related signaling is known to cause strong protection against diet-induced metabolic
disorders. The translational value of these prior findings, however, is dependent on whether such metabolically favorable
phenotype can be reproduced when myostatin blockade begins at an adult age. Here, we reported that AAV-mediated
delivery of a myostatin pro-peptide D76A mutant in adult mice attenuates the development of hepatic steatosis and
arteriosclerosis, two common diet-induced metabolic diseases. A single dose of AAV-D76A in adult Ldlr null mice resulted in
sustained expression of myostatin pro-peptide in the liver. Compared to vehicle-treated mice, D76A-treated mice gained
similar amount of lean and fat mass when fed a high fat diet. However, D76A-treated mice displayed significantly reduced
aortic lesions and liver fat, in association with a reduction in hepatic expression of lipogenic genes and improvement in liver
insulin sensitivity. This suggests that muscle and fat may not be the primary targets of treatment under our experimental
condition. In support to this argument, we show that myostatin directly up-regulated lipogenic genes and increased fat
accumulation in cultured liver cells. We also show that both myostatin and its receptor were abundantly expressed in
mouse aorta. Cultured aortic endothelial cells responded to myostatin with a reduction in eNOS phosphorylation and an
increase in ICAM-1 and VCAM-1 expression. Conclusions: AAV-mediated expression of myostatin pro-peptide D76A mutant
in adult Ldlr null mice sustained metabolic protection without remarkable impacts on body lean and fat mass. Further
investigations are needed to determine whether direct impact of myostatin on liver and aortic endothelium may contribute
to the related metabolic phenotypes.
Citation: Guo W, Wong S, Bhasin S (2013) AAV-Mediated Administration of Myostatin Pro-Peptide Mutant in Adult Ldlr Null Mice Reduces Diet-Induced
Hepatosteatosis and Arteriosclerosis. PLoS ONE 8(8): e71017. doi:10.1371/journal.pone.0071017
Editor: Manlio Vinciguerra, University College London, United Kingdom
Received April 2, 2013; Accepted July 1, 2013; Published August 1, 2013
Copyright:  2013 Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health grant RO1 DK059261 (WG) and DK078512 (SB). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: wguo2@partners.org
Introduction
Metabolic disorders, such as diabetes mellitus, nonalcoholic
fatty liver disease, and arteriosclerosis are leading causes of
morbidity and mortality in modern world. With the aging of
human populations, the prevalence of these inter-linked metabolic
disorders is increasing globally. We show here that myostatin, a
muscle-secreted growth and differentiation factor, may be a
potential therapeutic target for the prevention and treatment of
these metabolic disorders. Genetic disruption of myostatin gene
causes marked hypermuscularity and hypoadiposity [1–4]. Genetic
inactivation of myostatin in Ldlr null mice also alleviates diet-
induced hepatosteatosis and arteriosclerosis [5]. However, it is not
known whether similar metabolic improvement can be achieved
by myostatin antagonists in adults, an issue that is crucially
important for the relevant clinical applications.
We show here that administration of a protease-resistant
myostatin pro-peptide D76A mutant to adult mice, using the
AAV technology, induced a substantial reduction in liver fat
infiltration and aortic atheromatous lesions with only a mild
impact on body fat and lean mass. The strong association between
this metabolically favorable phenotype and robust ectopic
expression of myostatin pro-peptide in the liver of the D76A-
treated mice, with minor changes in muscle and fat mass, led us to
consider the hypothesis that myostatin may have direct effects on
hepatic lipid metabolism. We show here for the first time that
myostatin increases de novo hepatic lipogenesis in cultured liver
cells. In addition, we show that myostatin and its receptor are both
abundantly expressed in mouse aorta. Exposure of aortic
endothelial cells to myostatin resulted in activation of TGFb
signaling and reduced phosphorylation of endothelial NO synthase
(eNOS) in association with increased expression of pro-athero-
genic adhesion molecules ICAM-1 and VCAM-1. Our results
indicate that both liver and endothelium are direct targets of
myostatin which may be involved in diet-induced metabolic
disorders.
Materials and Methods
Materials
Myostatin pro-peptide D76A mutant fused with mouse IgG-Fc
was a gift from Dr. Se-Jin Lee (Johns Hopkins University,
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Baltimore, MD [6]). The recombinant product of this construct
(D76A-Fc) has been shown to moderately increase skeletal muscle
mass in adult mice [6,7]. The construct was used to generate an
adeno-associated virus (AAV9), using a commercial service (Vector
Biolabs, Philadelphia, PA), for sustained ectopic expression of the
myostatin pro-peptide D76A mutant [7–9]. Recombinant myos-
tatin mature peptide of mammalian origin was provided by
Amgen Inc (Thousand Oaks, CA). Luciferase reporter for TGFb/
myostatin signaling (3TP-Lux) was obtained from Addgene
(#11767, [10]). Renilla luciferase vector (#E6891) and dual
luciferase reporter assay kit (#E1910) were from Promega
(Madison, WI).
Animals and Diet
The animal protocol was approved by IACUC of Boston
University. Male Ldlr null mice were purchased from Jackson
Laboratory (Bar Harbor, MI). At eight week of age, mice were
analyzed by NMR and divided into two groups of similar body
composition. Animals were injected through tail vein with either
vehicle (saline) or AAV-D76A (461011 vg/ea, diluted in saline), a
dose similar to those used in previous studies [7]. AAV with no
functional gene products does not cause phenotypic changes in
Ldlr2/2 mice [11]. This was confirmed in our preliminary studies
with AAV-eGFP (not shown). Animals were maintained on regular
chow diet for 7 weeks to stabilize post-injection body composition.
All mice were then switched to a high fat diet (TD.09547, Harlan
Laboratories, Madison WI) for 12 weeks. This diet contains
48.4%, 21.4%, and 30.1% calories from carbohydrate, protein,
and fat, respectively, as well as 0.05% cholesterol.
Aortic Lesion Identification
After euthanasia, the aorta was stained en face with Sudan IV for
lipid-rich lesions as described before [5,12]. Degree of atheroscle-
rosis in the exposed aorta was presented as the percentage of
lesion-covered area in the tissue surface using NIH Image J
program. Sections of the aortic root (5 mm) near the sinus were
stained with hematoxylin and eosin (H&E) and immuno-stained
against MAC-3 and VCAM-1, as described [5,12]. Results of
immuno-staining was scored blindly following a modified score
system as described before (http://www.ihcworld.com/
ihc_scoring.htm). Masson’s Trichrome staining was performed
using commercial reagents (Market Lab Inc. Caledonia, MI).
Other Tissue Analysis
Selected fat depots, muscle groups, and liver were weighed and
expressed as a percentage of total body weight. Liver lipid staining
and tissue analyses for protein and RNA expression were
performed as described [5,12]. Expression of D76A in liver and
muscle was measured using real-time PCR using primers designed
for myostatin pro-peptide (NM_010834, nt 222–414, which
encompasses the D76A mutation site). For the liver, the
endogenous myostatin expression was low. Administration of
AAV-D76A induced a large increase in the expression level of pro-
peptide mRNA (Figure S1), a clear demonstration of robust
expression of the ectopic gene. In contrast, we were not able to
detect significant increase in muscle expression of myostatin pro-
peptide (Figure S1, right panel) or mature peptide (primer set for
nt 1015–1145, NM_010834, data not shown). Because full-length
myostatin (a single gene that encodes both pro-peptide and mature
peptide) is strongly expressed in muscle, the lack of difference in
pro-peptide expression between vehicle and D76A-treated mice
indicates that either the ectopic gene was not expressed or its
expression was low enough not to cause a detectable addition to
the endogenous gene. These results are consistent with previous
reports that AAV9, when injected through the tail vein, is
primarily expressed in the liver [9,13,14].
Plasma Lipids
Fasting blood samples (no food between 10 pm to 10 am) were
collected 10 weeks after high fat diet. Plasma lipids were measured
as described previously [5,12].
Insulin Tolerance and Pyruvate Tolerance
These tests were performed during week 11 after introduction of
the high fat diet. Briefly, insulin (Humalog, USP) was diluted in
sterile saline containing 0.1% BSA and injected (0.6 U/kg, 0.1 ml,
i.p.) after 4 h fasting. Sodium pyruvate (Gibco #11360-070) was
diluted in saline and injected (1.5 g/kg, 0.1 ml, i.p.) after overnight
fasting. Blood glucose was measured at baseline and every 15 min
after the injection for 2 hours.
Cell Culture
Human hepatoma HepG2 cells (a gift from Dr. Mengwei Zang,
Boston University) were grown as described [15]. Cells were
switched to low glucose DMEM (Gibco # 11885084) containing
1% fetal bovine serum (Gibco # 10438-018) overnight and then
treated with myostatin for different incubation periods and
harvested for Western or RT-PCR Analysis. Bovine aortic
endothelial cells (a gift from Dr. Yasuo Ido, Boston University)
were grown as described [16] in low glucose DMEM supplement-
ed with 10% calf serum (Sigma-Aldrich, #12133C) and primary
human aortic endothelial cells (Invitrogen, #C-006-5C) were
grown in a vendor-specified medium (Invitrogen, #C00625PA).
Cells were switched to serum-free medium overnight before
treatments.
Assays for Fatty Acid Oxidation and De Novo Fatty Acid
Synthesis
HepG2 cells were pre-labeled with trace amount of [9,10-3H]
oleate overnight (2 mCi per well in a 6 well plate), washed to
remove unincorporated tracers and incubated with myostatin
(100 ng/ml) for 24 h. Cells were washed again and incubated with
serum-free medium containing the same concentrations of
myostatin for another 8 hours. Acid-soluble metabolites released
from the cells were counted as the index for fatty acid oxidation
[17]. Similarly, HepG2 cells were incubated with myostatin for 24
hours and [1,2-14C] acetic acid was added for the last 3 hours of
the incubation. Lipid extracts were separated by TLC (Hexane :
ether : acetic acid at a ratio of 70:30:1) and visualized under iodine
vapor. The triglyceride-incorporated radioactivity was counted as
an index of fatty acid synthesis. Total cellular triglyceride content
was measured after 48 hour incubation and normalized to cellular
protein.
Immunohistochemistry
Mouse aorta root was fixed in formalin and sections were
prepared as described before [12]. Immunohistochemistry was
performed using a Zymed HistoMouse-SP Kit (AEC, Broad
Spectrum, Invitrogen #959544), following the manufacturer’s
instructions. Antibody for MAC3 was purchased from BD
Biosciences (#550292; San Jose, CA). Antibody for VCAM-1
was from Santa Cruz (#SC-1504, Santa Cruz, CA).
Western Analysis
Tissue and cellular homogenates were prepared for Western
analysis as described before [12]. First antibodies were purchased
from Cell Signaling (eNOS, #9586; phosphor-eNOS-Ser1177,
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#9570; phosphor-Smad3, #9520) and Santa Cruz (VCAM-1,
#SC-1504; beta-tubulin, #SC-9104; ActRIIB, #SC-5665; and
Smad2/3, #SC-6032).
Statistical Analysis
All numerical results are presented as means6SEM. Compar-
ison between two treatments were performed using Student’s t test.
Comparisons among multiple groups were performed using
ANOVA. Unless specified, all results obtained in tissue culture
experiments are representative of at least three experiments and
results obtained in tissue samples are representative of 5–10
animals of each group.
Results
Effects of D76A on Body Composition
Consistent with previous reports [7], we observed a modest
increase in lean body mass in mice following the injection of AAV-
D76A while the mice were maintained on a low fat chow (Figure
S2A). Seven weeks after the injection of AAV-D76A, the animals
were switched to a high fat diet to study the effect of D76A on diet-
induced metabolic responses. During the period of high fat diet,
the changes in lean and fat mass were similar between the vehicle
and D76A-treated animals (Figure S2B). Mice were euthanized
after twelve weeks of high fat diet, and individual tissues were
weighed. D76A-treated mice showed a 15% increase in quadriceps
and 5–10% increase in gastrocnemius and levator muscle groups
compared to the control group (Figure S2C). These differences
were relatively small as compared with the 100–150% increase
reported in the myostatin null mice [1–5] and were likely acquired
during the initial low fat feeding period. D76A-treated mice
showed a small decrease in inguinal fat but fat mass in perirenal,
epididymal, and mesenteric depots were not different between the
two groups (Figure S2C). This is in striking contrast to the global
hypoadiposity found in mice with life-long genetic myostatin
blockade [1–5,18], but in line with a recent study on diet-induced
metabolic disorders in mice with adult age myostatin deletion [19].
Effects of D76A on Aortic Atherosclerosis
The atheromatous lesions in the aorta were analyzed using the
en face method [5,12]. Most of the lesions were found in the aortic
arch and fewer lesions were present in the thoracic and abdominal
regions. D76A-treated mice had significantly fewer lesions than
vehicle-treated mice (Figure 1A, additional images of aorta lesion
staining are displayed in Figure S3). The mean lesion scores in the
aortic arch and the thoracic aorta were 57% and 83% lower in
D76A-treated animals than those in the control mice, respectively
(Figure 1A, lower panel). Hematoxylin and eosin staining of the
sections near the sinus of the aortic root revealed a significant
reduction of lesion size in D76A-treated mice compared with the
control mice (Figure 1B), consistent with the en face assessment.
Similar results were observed by trichrome staining of the aortic
roots, which further revealed a decrease in lipid core size and the
cholesterol clefts in mice treated with D76A (Figure S4).
To assess the inflammatory status of the lesions, we performed
immunostaining of the aortic root sections for MAC3, a marker of
macrophage infiltration. As shown in Figure 2A, vehicle-treated
mice showed greater MAC3 staining than D76A-treated mice. At
higher magnification, the lesions from D76A-treated mice were
found to contain fewer and less intensely stained MAC3-positive
cells than those from vehicle-treated mice (Figure 2A). Densito-
metric analysis revealed 41% reduction in MAC3 staining in
AAV-D76A-treated mice compared to controls (Figure 2A, lower
panel). As endothelial inflammation usually begins with the
adhesion of circulating inflammatory cells, an event facilitated
by the vessel wall production of vascular cell adhesion molecule-1
(VCAM-1), we also stained the aortic root sections for VCAM-1.
As shown in Figure 2B, D76A treatment reduced VCAM-1
staining by 30% compared to vehicle treatment.
Effects of D76A on Plasma Lipid Profile and Insulin
Sensitivity
Plasma cholesterol circulates in different forms of lipoproteins,
of which HDL is generally anti-atherogenic and the non-HDL
lipoproteins with variable triglyceride to cholesterol ratios are
proatherogenic. A high ratio between non-HDL and HDL
cholesterol usually correlates with accelerated lesion development,
and vice versus. As shown in Figure 3A, D76A treatment was
associated with lower plasma levels of triglycerides (p = 0.05), total
cholesterol (p = 0.03), and non-HDL cholesterol (p = 0.002), and a
trend towards higher HDL cholesterol (p = 0.06) and lower free
fatty acids (p = 0.08), in comparison to vehicle treatment. The
difference in each measurement, however, is relatively small as
compared to that observed in mice with genetic myostatin
knockout [5], considering that D76A-treatment correlates with a
greater suppression of aortic lesions. Whether D76A specifically
regulates subclass of pro-atherogenic plasma components, such as
oxidized lipoproteins, requires for further investigations.
Since a proatherogenic plasma lipid profile and insulin
resistance are often associated [20], we investigated the effects of
D76A treatment on insulin sensitivity. Fasting glucose (111612 vs.
107613 mg/dl, respectively) and fasting insulin concentrations
(2.9560.7 vs. 2.860.5 ng/ml, respectively) were similar between
the two groups. However, in the non-fasting state (4 h after food
removal in the morning), plasma glucose concentration was lower
in D76A-treated mice than in the controls (Figure 4B, left panel).
Since mice were provided free food access except for occasional
fasting (two days out of 3 months), non-fasting results would be
more physiologically relevant, which suggests that D76A-treated
animals have greater steady-state insulin sensitivity than the
control animals.
In response to a bolus injection of insulin, the kinetic change of
blood glucose did not differ between the two groups, but the
plasma glucose concentrations decreased to a lower level in the
D76A-treated mice than in the control mice. The area-under-the-
glucose-curve was significantly lower in D76A-treated mice than in
the vehicle-treated mice (AUC glucose 11629 vs. 17880 mg6min/
dL for D76A- and vehicle-treated mice, respectively, p = 0.006).
These results suggest that D76A-treated mice had better glycemic
control under steady-state condition but their acute response to
insulin administration was not dissimilar from that in vehicle-
treated animals. Because insulin-stimulated glucose uptake occurs
primarily in skeletal muscle, these results suggest that treatment
with D76A likely did not have a major impact on skeletal muscle
insulin sensitivity. Western analysis for selected key elements in the
insulin signaling cascade, including phosphorylated Akt and
p70S6, in the skeletal muscle and the adipose tissue revealed no
significant difference between the two groups (not shown). These
results contrast the findings in mice with genetic myostatin
blockade for which skeletal muscle is hyper-sensitive to acute
insulin administration [1–3,5,18] and highlights the phenotypic
difference between life-long genetic myostatin blockade and adult
age treatment with myostatin antagonists.
Unlike muscle and fat that take up glucose in response to
insulin, liver produces glucose in response to nutrient deprivation,
a process that is potently inhibited by insulin [21]. An increase in
basal (non-fasting) plasma glucose concentration can be a sign of
impaired insulin sensitivity in the liver so that it continues to
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produce glucose even when nutrient is plentiful (Figure 4B, left
panel). Hence, we performed the pyruvate tolerance test, which
measures the rise of blood glucose in response to a bolus injection
of pyruvate. As shown in Figure 3B (right panel), blood glucose
concentrations rose faster and to a higher level in the control mice
than in D76A-treated mice, suggesting that the latter had a greater
restraint on hepatic glucose output. Real-time PCR analysis
showed that D76A-treated mice had higher hepatic expression
levels of insulin receptor substrate 2 (IRS-2, Figure 3C) but not
IRS-1 (not shown). Of note, IRS-2 has been reported to play a
more important role than IRS-1 in hepatic insulin action [22].
Consistently, D76A-treated animals also displayed lower liver
expression of Pepck (Figure 3C), a key enzyme for gluconeogenesis
known to be transcriptionally suppressed by insulin [5,23].
Together, these results suggest that D76A-treated animals have
Figure 1. AAV-mediated expression of myostatin pro-peptide D76A mutant attenuates aortic atheromatous lesion accumulation in
Ldlr null mice. The animals were injected with either AAV-D76A (D76A) or vehicle (veh) at 8 weeks of age, placed on a high fat diet seven weeks
later, and euthanized after another 12 weeks. The entire aorta along with the aortic root was dissected for analysis. (A) En face staining with Sudan IV
for lipid-rich lesions (stained red). The lower panel shows the quantitative lesion scores (mean 6 SEM, n = 10). (B) Sections of the aortic root near the
sinus stained with hematoxylin and eosin (H&E) for lesions built up along the vessel wall (LC: lipid core, VW: vessel wall). The lower panel shows the
lesion area expressed as a percent of aortic area (mean6SEM, n= 10).
doi:10.1371/journal.pone.0071017.g001
Figure 2. AAV-D76A reduces expression of MAC-3 and VCAM-1 in aortic lesions. Sections adjacent to the sinus of the aortic roots were
immuno-stained using antibodies against (A) CD107b (MAC-3), a marker of macrophage infiltration, and (B) vascular cell adhesion molecule (VCAM-
1), an endothelial ligand that promotes the adhesion of lymphocytes, monocytes, eosinophils, and basophils (EC: endothelial cells, VW: vessel wall, LC:
lipid core). Lower panels display the quantitative analyses of immunostaining determined by densitometry (mean6SEM, n = 5).
doi:10.1371/journal.pone.0071017.g002
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Figure 3. AAV-D76A regulates plasma lipid profile and insulin sensitivity. (A) Plasma lipid profile: fasting plasma samples were obtained
after 10 weeks of high fat feeding and analyzed for triglycerides (TG), total cholesterol (Total C), HDL cholesterol (HDL-C), non HDL cholesterol
(nonHDL-C), and non-esterified fatty acids (NEFA). (B) Insulin tolerance test (ITT) and pyruvate tolerance test (PTT) performed after 11 weeks of high
fat feeding. For ITT, food was removed in the morning for four hours and then animals were injected with an insulin bolus (0.6 U/kg diluted in sterile
saline containing 0.1% albumin, i.p.). For PTT, food was removed overnight for 16 hours and then animals were injected sodium pyruvate (1.5 g/kg,
i.p. diluted in sterile saline). Blood glucose was measured using a glucometer and was plotted against time before and after the injections (n = 10,
mean 6 SEM). (C) Liver mRNA expression of insulin receptor substrate-2 (IRS-2) and phosphoenolpyruvate carboxykinase (Pepck) was analyzed by
real-time PCR (mean6SEM, n = 10).
doi:10.1371/journal.pone.0071017.g003
Figure 4. AAV-D76A attenuates liver fat infiltration, reduces liver triglycerides and cholesterol, and down-regulates mRNA
expression of selected lipogenic genes. (A) Cryo-sectioned liver samples (10 m) were stained with oil-red-O (red for lipids). Results are
representative of three animals per group. (B) Liver lipids were extracted by Folch’s method and analyzed for total cholesterol (Total C) and
triglycerides (TG) using commercial kits (mean 6 SEM, n = 10). (C) Liver mRNA expression was analyzed using qPCR; the upper panel shows genes
involved in lipid synthesis and the lower panel shows the genes involved in lipid oxidation (FAS: fatty acid synthase, SCD-1: stearoyl-CoA desaturase-
1, HMGCR: 3-hydroxy-3-methyl-glutaryl-CoA reductase, SREBP-1c: sterol regulatory element-binding protein 1, PPAR: peroxisome proliferator-
activated receptor, CPT: carnitine palmitoyl acyltransferase, MACD: medium chain acylCoA dehydrogenase). All PCR results were normalized to the
expression level of the house-keeping gene HPRT (mean 6 SEM, n = 10).
doi:10.1371/journal.pone.0071017.g004
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improved hepatic insulin sensitivity in comparison to vehicle-
treated mice under our experimental conditions.
Effects of D76A on Hepatosteatosis and Hepatic
Metabolic Gene Expression
Fatty liver is linked to diet-induced dyslipidemia and athero-
sclerosis [24]. We found that D76A-treated mice had significantly
lower liver fat than the control mice, as indicated by lipid staining
of liver sections (Figure 4A) and by lipid analysis of the liver
extracts (Figure 4B). D76A-treated mice also had lower hepatic
mRNA expression of key enzymes involved in lipogenesis,
including fatty acid synthase (FAS), stearoyl CoA dehydrogenase
(SCD-1), and HMG CoA reductase (HMGCR) (Figure 4C, upper
panel). These enzymes are largely regulated at the transcriptional
level [25]. Consistently, we found that liver expression level of
SREBP-1c, the master transcription regulator of hepatic lipogenic
enzymes [26,27], was lower in D76A-treated animals than in the
controls. In contrast to its inhibitory effect on lipogenic gene
expression, D76A treatment had no effect on hepatic expression of
important genes involved in fatty acid oxidation (Figure 4C, lower
panel). D76A treatment also did not affect the expression of
selected inflammatory cytokines, such as TNFa, MCP-1, and CRP
(Figure S4). Plasma IL-6 and MCP-1 were very low and were not
significantly affected by D76A (data not shown). The expression
levels of selected stress markers, C/EBP homologous protein-10
(CHOP-10) and heme oxygenase 1 (HO-1), were higher in the
liver of control mice than D76A-treated mice (Figure S5),
consistent with the notion that fat infiltration induces expression
of stress genes [28].
Liver is a Novel Direct Target of Myostatin
Because the atheroprotective phenotype mediated by AAV-
D76A injection was only weakly associated with changes in muscle
mass, but strongly associated with changes in hepatic fat and
robust hepatic expression of ectopic D76A, we considered the
possibility that metabolic protection may be a result of direct
blockade of myostatin signaling in the liver. To our knowledge,
direct effect of myostatin on liver has not been reported although
several studies have speculated such a possibility [3,29,30]. There
has been some uncertainty whether ActRIIB, the high affinity
receptor for myostatin [31,32], is expressed in the liver [33–36].
Using RT-PCR, we confirmed that ActRIIB was expressed in the
mouse liver although to a moderate extent (Figure 5A). When
recombinant myostatin was added to liver cells (HepG2) in culture,
ActRIIB expression was induced in a sustained manner
(Figure 5B). Similar induction of ActRIIB was confirmed in
isolated primary mouse hepatocytes (Figure S6). Myostatin rapidly
induced Smad3 phosphoylation (Figure 5C), an essential compo-
nent in the canonical myostatin signaling cascade [37,38].
Myostatin also increased the expression of selected genes
downstream of Smad3; including TGFb1, apoCIII, PAI-1, and
angiotensinogen II (AngII) (Figure 5D). PAI-1 and apoCIII are
known to be transcriptionally regulated by Smad3 [39,40],
whereas AngII can be induced by TGFb1 via a Smad-
independent pathway [41]. In line with these in vitro findings,
we show that inhibition of myostatin by D76A was associated with
decreased expression of TGFb1 and apoCIII in the liver (Figure
S5, lower panel). In addition, cells treated with myostatin also
showed increased expression of enzymes involved in lipogenesis,
such as SCD-1 and FAS (Figure 5D, lower panel). Consistent with
the increase in the expression of lipogenic genes, we found that
Figure 5. Liver is a direct target of myostatin signaling. (A) PCR measurement of the expression of myostatin receptor, ActRIIB, in the liver,
aorta, and skeletal muscle. (B) Myostatin induces sustained expression of its own receptor in HepG2 cells (mstn, 100 ng/ml, harvested at indicated
time points). (C) Myostatin induces Smad3 phosphorylation in HepG2 cells (100 ng/ml, 30 min). All results shown in (A–C) are representative of more
than three independent measurements. (D) Myostatin (100 ng/ml, 24 h) induces expression of Smad3 target genes in HepG2 cells (mean 6 SEM,
n = 4). (E) Myostatin (100 ng/ml) induces lipogenesis and lipid accumulation in HepG2 cells (means 6 SEM, n= 4).
doi:10.1371/journal.pone.0071017.g005
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myostatin increased fatty acid synthesis and lipid accumulation in
cultured liver cells (Figure 5E). There was no effect of myostatin on
fatty acid oxidation measured in parallel (data not shown). To our
knowledge, this is the first report of direct pro-lipogenic effect of
myostatin on liver cells, although others have shown that TGFb1,
which shares similar post-receptor signaling pathways with
myostatin, increases SCD-1 expression and increases lipid storage
in cultured liver cells [42,43].
Aortic Endothelium can be another Direct Target of
Myostatin
As shown in Figure 5A, the high affinity myostatin receptor,
ActRIIB, was robustly expressed in mouse aorta, so was
endogenous myostatin gene (Figure 6A). Within the aortic
endothelium, endothelial cells represent the first line of defense
against the insult from circulating factors. We thus evaluated the
direct effects of myostatin on aortic endothelial cells. Similar to
that found in the liver cells (Figure 5C), myostatin induced robust
Smad3 phosphorylation in both bovine and primary human aortic
cells (not shown). Figure 6B demonstrated that myostatin directly
induced activation of 3TP-Lux reporter gene for TGFb signaling
in bovine aortic endothelial cells, an effect that requires
cooperation between both type-II and type-I receptors [10]. Since
type-I receptors are shared between myostatin and TGFb [44], the
induction of 3TP-Lux by myostatin confirms functional activation
of myostatin signaling in the aortic endothelial cells. Furthermore,
incubation with myostatin induced the expression of intracellular
cell adhesion molecule 1 (ICAM-1, Figure 6C), down-regulated
steady-state phosphorylation/activation of endothelial NO syn-
thase (eNOS, Figure 6D) and up-regulated the expression of
vascular cell adhesion molecule (VCAM-1, Figure 6D) in primary
cultured human aortic endothelial cells (HuAEC). As eNOS
protects the endothelium against insults from circulating inflam-
matory cytokines and oxidized lipoproteins [45] while ICAM-1
and VCAM-1 promote monocyte adhesion and lesion develop-
ment [46], these results suggest that myostatin blockade may have
a favorable effect on the endothelium under certain physiological
conditions, such as hyperlipidemia, by reducing local expression of
pro-adhesion molecules, a hypothesis that requires further
investigations.
Discussion
Our data provide the first evidence that AAV-mediated
administration of myostatin pro-peptide D76A mutant in adult
mice attenuates diet-induced aortic atherosclerosis and hepatos-
teatosis in Ldlr null mice. These data provide a new rationale to
support the development of anti-myostatin strategies for the
prevention and treatment of atherosclerosis and hepatosteatosis in
humans.
It is important to emphasize that although genetic modulation is
useful to validate a concept, the feasibility for translational
medicine is entirely dependent on whether a favorable phenotype
of a genetic model can be successfully recapitulated by post-natal,
especially adult age, interventions. Life-long genetic myostatin
blockade causes dramatic hyper-muscularity and hypo-adiposity
[1–3,5]. Hence, it is not clear whether the associated metabolic
phenotype, i.e. strong protection against diet-induced insulin
resistance, hepatosteatosis, and atherosclerosis [1–3,5], is directly
related to myostatin signaling or secondary to the extreme muscle
hypertrophy. Indeed, it has been shown that life-long muscle-
specific transgenic myostatin blockade was sufficient to reproduce
the phenotype of mice with global myostatin knockout, unequiv-
ocally proving that dramatic muscle hypertrophy alone is sufficient
to cause global metabolic protections [1,3,18]. However, such
extremely hypertrophic muscle phenotype was not reproduced in
mice with adult age myostatin inhibition [6–9,19,47](this work). In
addition, life-long genetic myostatin blockade, global or muscle-
specific, prevents diet-induced increment in fat mass [1–3,5], a
phenotype that was also not reproducible in mice with adult age
myostatin inhibition ([19], this work). However, despite a modest
impact on body composition, adult age myostatin inhibition does
prove effective in protection against diet-induced fatty liver ([19],
this work) and atherosclerosis (this work), thus prompting us to
consider organ-specific effect of myostatin (and its inhibitors) on
metabolic regulations without being overwhelmed by the hyper-
muscular phenotype found in mice with life-long genetic myostatin
blockade.
Although protection against diet-induced hepatosteatosis has
been documented in mice with genetic myostatin blockade for life
or induced at adult age [1–3,5,19], it is generally considered as
secondary to the impact on muscle health [1,30]. To our
knowledge, the results provided in this work are the first evidence
that myostatin can participate in hepatic metabolic regulation
through direct interaction with liver cells. We show that liver cells
express high affinity receptor for myostatin and respond to
myostatin stimulation by increasing phosphorylation of Smad3
and expression of Smad3-responsive genes including SCD-1 [42],
a key lipogenic gene in fatty liver development [48]. Furthermore,
we have shown that myostatin induces the expression of selected
lipogenic genes and increases lipid accumulation in the cultured
liver cells. This finding is congruent with the reports that TGFb1,
which shares the type I receptor with myostatin, induces lipogenic
gene expression and increases lipid accumulation in liver cells
[42,43].
A second novel finding reported in this work is the direct effect
of myostatin on aortic endothelial cells. While liver plays a central
role in systemic lipid metabolism, aortic atherosclerosis starts with
endothelial damage and monocyte adherence, which set the stage
for lipid uptake and foam cell formation. We show here that
myostatin and its receptor are robustly expressed in the aortic
tissue. In addition, we provide evidence that myostatin directly
interacts with cultured bovine aortic endothelial cell line and
primary human aortic endothelial cells to inhibit eNOS activation
and up-regulate the expression of ICAM-1 and VCAM-1. These
effects potentially could contribute to arterial lesion development
and warrants further evaluations.
It should be pointed out that while diet-induced hyperlipidemia
is an established risk factor for atherosclerosis, the effect of D76A
on plasma lipid profile in our animals was relatively moderate,
which alone may not explain the marked reduction in aortic
lesions. Other mechanisms can be involved. For instance, liver
secretion of D76A may help to sequester circulating myostatin in
its inactive form; reducing its impact on endothelial production of
adhesive molecules. In addition to regulation of liver lipogenesis,
myostatin blockade by D76A may also change some of the
properties of liver secretion, such as the size, composition, and
redox state of the VLDL particles, which can result in less pro-
atherogenic lipid particles in circulation. Furthermore, excessive
lipid accumulation is often associated with tissue inflammation.
Although D76A did not change the expression of selected
common inflammatory markers in the liver (Figure S5) and in
circulation (data not shown), we show that D76A reduced liver
expression of TGFb1 and apoCIII, both can be pro-atherogenic
[49,50]. D76A also reduced liver expression of stress marker
CHOP-10 and HO-1, implying less oxidative damage in the liver
which can alter the antioxidant defense in secreted lipid particles
as well as other systemic redox regulators. Further studies are
Myostatin, Hepatosteatosis, and Atherosclerosis
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e71017
required to investigate these and other possible mechanisms to
fully understand the remarkable phenotype observed in this study.
The pioneering work of Lee and others have emphasized the
important evolutionary role of myostatin as a chalone that
restrains unbridled muscle growth [31]. The findings of the
current study suggest that myostatin may also promote hepatic fat
stores and facilitate vessel wall wound healing; both can be
important pro-survival evolutionary adaptations during periods of
nutrient paucity. However, in the contemporary period of nutrient
excess coupled with physical inactivity, the same function of
myostatin could contribute to metabolic dys-regulations [51–55].
In summary, this work has demonstrated that (i) myostatin may
participate in signal regulation and modulate metabolic outcomes
through direct interactions with target cells in the liver and the
aorta; (ii) myostatin antagonists might have a therapeutic role in
the prevention or treatment of hepatosteatosis and atherosclerosis.
These findings set the stage for further investigations of the
potential therapeutic applications of myostatin antagonists for
metabolic disorders as well as the mechanisms by which myostatin
signaling pathways intersect with the metabolic regulatory
pathways.
Supporting Information
Figure S1 Expression of myostatin propeptide (nt 222–214,
NM_010834) in the liver (left panel) and quadriceps muscle (right
panel) between vehicle and D76A-treated animals, normalized to
the expression of house-keeping gene HPRT. Each bar represents
one individual animal.
(TIF)
Figure S2 Effects of myostatin inhibition by AAV-D76A on
body composition. A: Time-dependent changes in body lean mass
after injection of AAV-D76A during the first 7 weeks while the
animals were fed normal chow. B: The net increase in total lean
(left) and fat (right) mass during the first seven weeks (left panel),
the 12 week of high fat diet (middle panel), and total experimental
period (right panel). Results of A&B were obtained by NMR
(mean +/2 SE, N=10, *p,0.05). C: Tissue weight expressed as
percentage of total body mass (means +/2 se, n = 10). Mean body
mass was not significantly different between the two groups
(43.29+/22.96 g and 41.49+/23.62 g, for vehicle- and D76A-
treated groups, respectively, n = 10).
(TIF)
Figure S3 Effects of AAV-D76A on aorta lesion accumulation:
additional en face aortic images supplemental to Figure 1. The
microphotographs were taken on a different facility and more
yellowish background color was recorded. Lipid-rich lesions are
stained red with Sudan IV. The results clearly illustrated a
reduction of aortic lesions in D76A-treated mice compared to the
vehicle-treated ones.
(TIF)
Figure S4 Trichrome staining of lesions from the vehicle and
D76A- treated mice. Red stains for muscle, including the smooth
muscle in the fibrous cap at the lumen side, blue stains for
collagen, white foamy structure indicates lipid-rich foam cell
Figure 6. Aorta is a direct target of myostatin signaling. (A) PCR analysis of aortic expression of endogenous myostain mature peptide (mstn,
nt 1015–1145, NM_010834), using skeletal muscle as the positive control and liver as the negative control (mean6 SEM, n = 3). Of note, while actin is
often considered as an abundant house-keeping gene in multiple tissues, its expression level may not be cross-comparable. Hence, the results
presented here only demonstrated that myostatin is abundantly expressed in the aorta but does not indicate that the expression is to a similar level
found in the muscle. (B) Myostatin induces activation of its reporter gene 3TP-Lux in bovine aortic endothelial cells (BAEC, mean 6 SEM, n = 3). (C)
Myostain induces ICAM-1 expression in primary cultured human aortic endothelial cells (HuAEC). TGFb1 (T: 10 ng/ml) served as a positive control
(M50: myostatin 50 ng/ml, M100:100 ng/ml, 3 h incubation in serum-free Medium 199 supplemented with oxLDL 0.025 mg/ml to raise the basal
expression of ICAM-1) (mean 6 SEM, n= 4). (D) Myostatin (100 ng/ml) down regulates the expression of phosphor-eNOS and up regulates VCAM-1
expression in HuAEC. Results are reflective of three independent experiments.
doi:10.1371/journal.pone.0071017.g006
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deposits, needle-like structures are cholesterol clefts from necrotic
lipid core. Results are representative of five animals of each group.
(TIF)
Figure S5 Changes in liver transcripts after myostatin inhibition
by AAV-D76A. Liver mRNA was analyzed by RT-qPCR for
expression of genes downstream of TGFb/mystatin signaling:
TGFb1, ApoCIII, ANG-II and PAI-I (lower panel), stress-related
genes: BIP, CHOP, and HO-1 (upper panel), and inflammatory
genes: MCP-1, TNFa, and CRP (middle panel). Results are shown
as means +/2 se, n = 10, t test).
(TIF)
Figure S6 Primary mouse hepatocytes were isolated by the
portal vein collagenase perfusion method as described (Li WC,
Ralphs KL, Tosh D. Isolation and culture of adult mouse
hepatocytes. Methods Mol Biol. 2010;633:185–96. PMID:
20204628). After attachment, medium was replaced by serum-
free M199 overnight. Myostatin (mstn) was added the next
morning and incubated for 5 hours before RNA harvest.
Expression of ActRIIB (NM_007397) was measured by qPCR (f-
primer: CATTGCTGCCGAGAAACGAG; r-primer:
TCCACGTGATGATGTTCCCC ). Exogenous myostatin in-
duces expression of its own receptor ActRIIB in a bell-shape like
dose-dependent manner.
(TIF)
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